Treatment for Dyspepsia

Phase-Based Progress Estimates
University of California Los Angeles, Los Angeles, CA
Dyspepsia+1 More
All Sexes
Eligible conditions

Study Summary

This study is evaluating whether a new type of capsule endoscopy can be used to evaluate gastroparesis and functional dyspepsia.

See full description

Eligible Conditions

  • Dyspepsia
  • Gastroparesis

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

This trial is evaluating whether Treatment will improve 5 primary outcomes in patients with Dyspepsia. Measurement will happen over the course of Through study completion, an average of 1 year.

Year 1
Dyspepsia Severity Scale symptom ratings at baseline and during the study at timepoints with discomfort if present.
Frequency and direction of contractions
Largest diameter of the pylorus
Number and location of luminal transit markers in the antrum, fundus, and overall
Procedure related adverse events

Trial Safety

Safety Progress

1 of 3

Trial Design

0 Treatment Group

This trial requires 17 total participants across 0 different treatment group

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: through study completion, an average of 1 year
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly through study completion, an average of 1 year for reporting.

Who is running the study

Principal Investigator
L. C.
Lin Chang, MD
University of California, Los Angeles

Closest Location

University of California Los Angeles - Los Angeles, CA

Eligibility Criteria

This trial is for patients born any sex aged 18 and older. There are 10 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
Evidence of delayed gastric emptying documented with a standard 2 hour or 4 hour gastric emptying scintigraphy exam
Absence of mechanical obstruction
Exhibits cardinal symptoms of early satiety, post-prandial fullness, nausea, vomiting, bloating, and upper abdominal pain
Gastrointestinal cardinal symptom index (GCSI) score > 0 (i.e., the presence of at least mild severity of >1 of 3 symptoms of nausea/vomiting, postprandial fullness/early satiety, and/or bloating).
Functional Dyspepsia
Criteria fulfilled for the last 3 months with symptom onset at least six months prior to diagnosis
No evidence of organic, systemic, or metabolic disease that is likely to explain the symptoms on routine investigations (including at upper endoscopy)
Meet criteria for Epigastric pain syndrome and/or Postprandial distress syndrome
Epigastric Pain Syndrome At least 1 of the following symptoms at least 1 day per week

Patient Q&A Section

Ask a question about the study

Other questions from users

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any geographic restrictions to consider when applying for this trial?

Patients from any state can participate in this trial, so long as they are able to attend all treatment sessions.

Will my insurance cover participating in this trial?

In order to understand how insurance coverage works for this trial, you will need to contact the study coordinator.

See if you qualify for this trial
Get access to this novel treatment for Dyspepsia by sharing your contact details with the study coordinator.